tobia
broger
colleagu
report
evalu
urin
pointofcar
test
tuberculosi
target
lipoarabinomannan
author
test
frozen
specimen
retriev
biorepositori
acknowledg
limit
studi
potenti
differ
analyt
perform
frozen
fresh
urin
sampl
investig
effect
freez
lipoarabinomannan
concentr
unprocess
patient
urin
measur
concentr
lipoarabinomannan
urin
sampl
freez
polyethylen
terephthal
tube
use
inhous
elisa
sampl
frozen
minimum
day
retest
mean
lipoarabinomannan
concentr
decreas
pgml
sd
pgml
sd
averag
loss
result
indic
fresh
sampl
contain
detect
lipoarabinomannan
might
improv
sensit
describ
test
use
fresh
sampl
might
crucial
patient
expect
low
lipoarabinomannan
concentr
count
higher
cell
per
depend
handl
urin
freez
differ
protein
content
ph
dramaticurin
alkalis
time
protein
content
drop
freezethaw
factor
could
affect
perform
later
flow
test
elimin
variabl
urin
sampl
lead
assay
develop
produc
less
robust
test
unabl
handl
spectrum
fresh
urin
could
yield
high
rate
fals
posit
basi
result
crucial
chang
urin
freez
conclud
differ
fresh
frozen
urin
sampl
nontrivi
matter
declar
compet
interest
lancet
infecti
diseas
kayvon
modjarrad
colleagu
report
result
first
inhuman
clinic
trial
vaccin
candid
middl
east
respiratori
syndrom
mer
coronaviru
vaccin
induc
humor
cellular
mer
coronavirusspecif
immun
respons
data
suggest
potenti
valu
protect
human
mer
coronaviru
infect
howev
vaccin
epidemiolog
survey
conclud
camel
contact
healthcar
worker
patient
household
contact
highrisk
group
therefor
target
group
vaccin
howev
mani
infect
case
sourc
infect
could
identifi
unpredict
infect
make
hard
prevent
human
infect
vaccin
postexposur
prophylaxi
zoonot
diseas
prevent
control
onesid
diseas
prevent
either
human
anim
often
ineffici
sever
acut
respiratori
syndrom
sar
success
preced
contain
emerg
coronavirus
base
elimin
primari
reservoir
although
pathogen
sar
mer
coronavirus
two
major
factor
lead
differ
control
result
first
although
number
human
sar
case
greater
mer
due
socal
superspread
strain
contrast
clade
mer
coronaviru
share
camel
human
indic
mer
coronaviru
easili
spillov
camel
infect
human
control
diseas
camel
two
possibl
exist
mass
slaughter
infect
anim
vaccin
unfortun
serolog
survey
show
high
preval
mer
coronavirusneutralis
antibodi
dromedari
camel
therefor
seem
imposs
elimin
diseas
mass
slaughter
posit
anim
vaccin
camel
seem
choic
licens
vaccin
camel
current
avail
although
sever
vaccin
develop
addit
report
also
immunogen
camel
camel
use
routin
research
laboratori
would
hard
attain
enough
anim
work
moreov
wwwthelancetcominfect
vol
octob
robust
longlast
protect
immun
respons
week
mer
dna
vaccin
induc
humor
cellular
respons
particip
particip
respect
two
particip
maintain
neutralis
antibodi
end
studi
thu
gener
humor
cellular
immun
respons
might
equat
longterm
protect
phase
dna
vaccin
develop
us
militari
aptli
illustr
advanc
technolog
vaccin
platform
clinic
trial
design
bioinformat
togeth
seriou
invest
stakehold
provid
opportun
rapid
vaccin
develop
evalu
countri
mer
endem
must
invest
serious
human
camel
vaccin
develop
continu
outbreak
mer
coronaviru
year
first
discov
effect
human
vaccin
could
ideal
way
prevent
spread
evolut
viru
logist
issu
small
sporad
number
new
mer
case
differ
geograph
locat
need
overcom
coordin
approach
research
someth
need
advanc
rapidli
current
pace
research
develop
dna
vaccin
candid
mer
coronaviru
vaccin
allow
rapid
design
product
advanc
clinic
within
month
preclin
candid
vaccin
select
encourag
result
phase
mer
dna
vaccin
studi
advanc
quickli
includ
studi
adequ
number
elderli
comorbid
popul
care
consider
safeti
longev
protect
respons
therebi
mitig
futur
outbreak
allevi
diseas
burden
suscept
populationselderli
peopl
immunosuppress
peopl
healthcar
worker
big
studi
biosafeti
facil
limit
restrict
vaccin
test
camel
increasingli
recognis
one
health
approach
need
effect
investig
prevent
control
emerg
zoonot
diseas
context
emerg
zoonos
human
veterinari
medicin
must
work
togeth
erad
mer
coronaviru
dromedari
camel
primari
condit
control
diseas
arabian
peninsula
viru
continu
circul
camel
might
attain
new
mutat
enabl
humantohuman
transmiss
result
gener
superspread
strain
comprehens
mer
prevent
control
effort
focu
human
vaccin
also
camel
vaccin
advanc
dna
vaccin
second
phase
trial
need
overcom
oper
logist
challeng
must
target
risk
succumb
diseas
high
mortal
sever
diseas
seen
mer
posit
correl
age
presenc
comorbid
includ
chronic
liver
kidney
heart
diseas
diabet
immunosuppress
condit
furthermor
host
immun
respons
mer
coronaviru
could
contribut
diseas
sever
outcom
thu
vaccineinduc
immun
respons
popul
highrisk
characterist
could
potenti
harm
effect
barrier
encount
sever
acut
respiratori
syndrom
coronaviru
vaccin
develop
year
ago
might
also
hold
true
mer
coronaviru
therefor
mer
coronaviru
vaccin
must
specif
target
vulner
popul
assess
safeti
gener
